Invivyd, Inc. IVVD
0.60 USD +0.02 (+4.33%)
At closeNov 11, 2026, 7:27 PM EST
0.60 0.00 +0.65%
After hours · Nov 11, 7:27 PM ET
0.5801 Day range 0.6099
0.528 52-week range 3.07
- YTD
- -75.74%
- 1 year
- -63.68%
News
globenewswire.com Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW HAVEN, Conn., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on November 1, 2026, Invivyd granted seven newly hired non-executive employees options to…
benzinga.com Invivyd Presents Preclinical Data Showing Measles Antibody Candidate VMS063 Demonstrates Potent Antiviral Activity Against Contemporary Measles Fusion Protein Variants VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary…
globenewswire.com Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026 VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary…
benzinga.com Invivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome The Phase 2 FLINTLOCK clinical trial includes the following study features:Randomized, double-blind, placebo-controlled, proof-of-concept studyTests Invivyd’s monoclonal antibody VYD2311, an…
globenewswire.com Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the initiation of FLINTLOCK, a Phase 2 clinical trial evaluating the safety,…
defenseworld.net Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval Invivyd (NASDAQ: IVVD) reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined…
globenewswire.com Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW HAVEN, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on October 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase…
marketbeat.com Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval Invivyd NASDAQ: IVVD reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined…
benzinga.com Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody Invivyd Inc. (NASDAQ:IVVD) on Tuesday announced topline results from its Phase 3 LIBERTY study of its investigational COVID-19 monoclonal antibody candidate.
benzinga.com Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19 antibody levels.
seekingalpha.com Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript
benzinga.com Invivyd Announces Clinically Meaningful And Statistically Significant Topline Data From Its LIBERTY Phase 3 Study Evaluating Safety And Tolerability Of VYD2311, COVID-19 vaccine COMIRNATY, And VYD2311 Co-Administered With mRNA-Based COVID-19 Vaccine VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the…
globenewswire.com Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, clinically meaningful, and statistically significant topline data from the LIBERTY Phase 3,…
marketwatch.com These beaten-down stocks could bounce back in January, if history is any guide Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47%…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Greenland Mines (NASDAQ:GRML) stock rose 108.1% to $5.93 during Monday's pre-market session. The market value of their outstanding shares is at $9.0 million. Cue Biopharma (NASDAQ:CUE) stock…
marketbeat.com 3 Small-Cap Biotechs With Binary Catalysts on the Calendar For small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting…
globenewswire.com Invivyd to Participate in Upcoming September Investor Conferences NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will…
defenseworld.net BlackRock Inc. Takes $14.08 Million Position in Invivyd, Inc. $IVVD BlackRock Inc. bought a new stake in shares of Invivyd, Inc. (NASDAQ: IVVD) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.…
globenewswire.com Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on September 1, 2026, Invivyd granted six newly hired non-executive employees options to…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. Lakewood-Amedex…- benzinga.com Invivyd Continues To Expect Top-Line Data From VYD2311 Program Around The End Of Q3 2026 Invivyd continues to expect top-line data from the VYD2311 program around the end of Q3 2026. At that time, Invivyd plans to either unblind the DECLARATION study in its entirety and submit a…
benzinga.com Invivyd Appoints Marc Elia As CEO Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategyAjay Royan, Founder of Mithril Capital and a founding,…
globenewswire.com Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as…- benzinga.com Cantor Fitzgerald Reiterates Overweight on Invivyd, Maintains $10 Price Target Cantor Fitzgerald analyst Josh Schimmer reiterates Invivyd (NASDAQ:IVVD) with a Overweight and maintains $10 price target.
zacks.com Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.12 per share a year ago.
globenewswire.com Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights NEW HAVEN, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the second quarter ended June 30, 2026, and recent business highlights.
globenewswire.com Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on August 1, 2026, Invivyd granted ten newly hired non-executive employees options to purchase an…
benzinga.com The FDA Sent Invivyd An Advance Termination Notice For Pemgarda (Pemivibart) Emergency Use Authorization Following US Department Of Health And Human Services’ Announcement Of Advanced Notice Of Termination Of Covid-19 EUA Declaration On June 30, With Effective Date Of June 29, 2027 U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027 Consequently, Invivyd received from the U.S. Food…
globenewswire.com Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA NEW HAVEN, Conn., July 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has sent Invivyd a Notice of Termination for the…
globenewswire.com Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an…
benzinga.com Invivyd Completes Enrollment Phase 3 LIBERTY Trial Of Covid-19 Monoclonal Antibody VYD2311 With An mRNA Covid-19 Vaccine, Topline Data Expected in Q3 2026 Data from LIBERTY can provide important insight into the VYD2311 clinical profile by direct comparison between COVID antibody prophylaxis and COVID vaccine.LIBERTY is part of Invivyd's broader…- benzinga.com HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $10 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $10 price target.
benzinga.com Invivyd Dosed The First Participants In LIBERTY Phase 3 Trial Of VYD2311 Alone, And VYD2311 Co-administered With A Covid-19 Vaccine In Healthy Adults; Topline Data Is Expected In Q3 2026, To Accompany Anticipated Data From Pivotal DECLARATION Study LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA…
benzinga.com Invivyd Completes Enrollment In DECLARATION Phase 3 Trial of VYD2311 To Prevent Symptomatic Covid-19; Top-line Data Expected In Approximately Late Q3 2026 DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of symptomatic COVID-19 versus placebo, at three months, from…
benzinga.com Gemini Space Posts Upbeat Q1 Results, Joins Figma, Sutro Biopharma And Other Big Stocks Moving Higher On Friday Dow Jones falls 400 points, while Gemini Space Station Inc (NASDAQ: GEMI) sees 25.7% jump after strong financial results and $100M investment.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Invivyd Reports Q1 2026 Results: Full Earnings Call Transcript 
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com Invivyd Q1 EPS $(0.13) Misses $(0.07) Estimate, Sales $13.744M Miss $18.050M Estimate Invivyd (NASDAQ:IVVD) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.07) by 85.71 percent. This is a 7.14 percent increase over losses of $(0.14)…
- benzinga.com Invivyd EVADE Trial Data Reveals Monoclonal Antibody VYD2311 Demonstrates Minimal Tolerability Issues Versus COVID mRNA Vaccination Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issuesResults allow for…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com BlackBerry Posts Upbeat Q4 Results, Joins Constellation Brands, Marvell Technology And Other Big Stocks Moving Higher On Thursday U.S. stocks fell, Dow Jones down 100+ points. BlackBerry (NYSE:BB) reported strong Q4 results and sales guidance. Shares rose 12.2%. Other top gainers: MGRT, STAA, FBRX, EOSE, MFI, SATL, IVVD, MRLN,…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Earnings Scheduled For March 5, 2026
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday 
benzinga.com Nasdaq Down 1%; Medtronic Earnings Top Views